Tocilizumab for Fulminant Programmed Death 1 Inhibitor-Associated Myocarditis

J Thorac Oncol. 2020 Mar;15(3):e31-e32. doi: 10.1016/j.jtho.2019.09.080.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Electrocardiography
  • Humans
  • Lung Neoplasms*
  • Myocarditis* / chemically induced

Substances

  • Antibodies, Monoclonal, Humanized
  • tocilizumab